{
    "nct_id": "NCT03821272",
    "official_title": "A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients in Remission to Reduce Recurrence Regardless of HPV Status",
    "inclusion_criteria": "1. Able to provide informed consent\n2. Male or female 18 years of age or older\n3. Squamous cell carcinoma of the head and neck who have completed curative therapy (surgery and/or radiation and/or chemotherapy) therapy within the previous 120 days\n4. Performance status of Eastern Cooperative Oncology Group (ECOG) 0-2\n5. No Evidence of Disease (NED) based on clinical and/or radiographic evaluations\n6. Vital Signs recorded\n\n   1. Blood pressure (≤160/95 mm Hg acceptable)\n   2. Heart rate (50-100 beats per min acceptable)\n   3. Respiratory rate (≥ 12 ≤25 breaths per min acceptable)\n   4. Temperature (≤100°F acceptable)\n7. Blood work done at Screening Visit\n\n   1. White count (≥3x109/L acceptable)\n   2. Hemoglobin (≥ 7 g/dL acceptable)\n8. Willing and able to comply with the requirements of the protocol\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "1. Positive urine pregnancy test for women of childbearing potential\n2. Being pregnant or attempting to be pregnant within the period of study participation\n3. Women who are breast feeding or plan to breast feed within the period of study participation\n4. Patients who are allergic to Candin® or yeast\n5. History of severe asthma requiring emergency room visit or hospitalization within the past 5 years\n6. Patients who have previously received PepCan\n7. History of recurrence of squamous cell carcinoma of the head and neck\n8. If in the opinion of the Principal Investigator or other Investigators, it is not in the best interest of the patient to enter or continue in this study",
    "miscellaneous_criteria": ""
}